Lung Cancer Outcome Improvement Through Genotype-Specific Care
ENGAGE! · 22.06.2026 · 6 (1) · 45-51
DOI: 10.18060/29918 ↗Kurz gefasst
Fachartikel in der Zeitschrift ENGAGE!, online erschienen am 22.06.2026. Verfasst von Margaret Wallen und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Lung cancer is the leading cause of cancer-related death for men and women in the state of Indiana and across the country.While earlier diagnosis and new pharmaceutical innovations have improved five-year survival rates, disparities in access and responsiveness to new therapeutics continue to prevent major improvements in lung cancer prognosis.A more personalized approach to treatment comes from genetically characterizing the tumors of lung cancer patients through the most comprehensive genetic screening available.Biomarkerguided treatment for lung cancer patients shows markedly improved responsiveness to treatment compared to traditional therapeutics.While many states, including Indiana, have passed legislation to mandate insurance reimbursement of biomarker testing, the policy does not explicitly include the most advanced and meaningful screening.Biomarker screening to date is driven by determining eligibility for specific targeted therapies, but its true power could be realized by including more comprehensive characterizing to allow correlation between genetic abnormalities of tumors, disease progression, and responsiveness to treatment.Utilizing this broaderbased strategy will improve treatment and prognosis for current patients and provide data for the discovery of new potential therapeutic targets. Biomarker testing for lung cancer can provide more personalized treatment and better prognosis for patients, but available technology is underutilized.Prior to the early 2000s, treatment for lung cancer was largely determined based on the origin of the cells involved (squamous vs. nonsquamous) and tumor node metastasis (TMN) stage (Spiro & Silvestri, 2005).Using these diagnostic benchmarks, combination therapies -including platinum-based chemotherapieswere the standard of care (Schiller et al., 2002).While genetic analysis was emerging, it was not used to guide differential diagnosis (Lynch et al., 2004).Prognosis following diagnosis of lung cancer, particularly late stage, was bleak.Response rates ranged from 19-32%, with a median survival rate of less than 8 months, and a 1-year survival rate of around 30% (Schiller et al., 2002). ENGAGE! | Inclusive Engagement in Cancer Research & Practice
Zitieren
APA
Wallen, M., Settles, A., & Evans, A. (2026). Lung Cancer Outcome Improvement Through Genotype-Specific Care. ENGAGE!, 6(1), 45-51. https://doi.org/10.18060/29918
Vancouver
Wallen M, Settles A, Evans A. Lung Cancer Outcome Improvement Through Genotype-Specific Care. ENGAGE!. 2026;6(1):45-51. doi:10.18060/29918
BibTeX
@article{Wallen2026,
author = {Wallen, Margaret and Settles, Alex and Evans, Alexis},
title = {Lung Cancer Outcome Improvement Through Genotype-Specific Care},
journal = {ENGAGE!},
year = {2026},
volume = {6},
number = {1},
pages = {45--51},
doi = {10.18060/29918}
}
EUVIMED